Articles

What testosterone therapy really is, who it is indicated for, how it is prescribed in Spain and what the evidence says about its benefits and its risks, without the hype or the anti-ageing promises.

Prediabetes is not an established disease, but a state of risk. We explain what the numbers mean, why it matters beyond blood sugar and what the evidence says about how to manage it.

For twenty years, a single study from 2002 frightened an entire generation of women and their doctors. We now know its findings were misread. Here's what menopausal hormone therapy really is, who it makes sense for and what its real risks are, with the figures on the table and the nuances that go with them.

Regaining some weight after stopping a GLP-1 receptor agonist is an expected physiological phenomenon, not a failure of willpower. We explain what the evidence from the semaglutide and tirzepatide trials shows, what comes back and what doesn't, and where things stand in Spain.

Low testosterone has become a catch-all explanation for tiredness or low mood, but genuine hypogonadism is something else: it requires specific symptoms plus a confirmed blood test, and it is less common than the marketing suggests. Here is what the evidence says, which symptoms really count, and why a single low reading diagnoses nothing.

Finasteride is one of the treatments authorised in Spain for androgenetic alopecia in men. We explain how it acts on DHT, what the trials show, which side effects the EMA has been monitoring since 2025 and why the decision is always an individual medical assessment.

Baricitinib (Olumiant) is the first systemic drug authorised in Spain for severe alopecia areata: in adults and in adolescents aged 12 and over, and publicly funded in adults. Here is what it is, what the trials found and where the caveats lie.

Perimenopause is the transition towards menopause, not a single point in time. We explain what it is, why it happens, how long it usually lasts and what the evidence says about the symptoms and their treatments, with nuance and without scaremongering.

Veoza is the first non-hormonal medicine authorised in Spain for moderate to severe menopausal hot flushes. What it is, what the SKYLIGHT trials found and why it requires liver monitoring.

Androgenetic alopecia is the most common cause of hair loss and comes down to a mix of hormones and genetics. Here's what happens inside the follicle, how it progresses and which myths are worth leaving behind.

Metabolic fatty liver disease (MASLD) affects more than 30% of adults and is closely tied to weight, insulin resistance and diabetes. Here we explain what it is, why it happens, what the evidence says about losing weight and the new medicines, and which myths are worth dismantling.

Two drugs that raise your own testosterone without switching off fertility. The idea looks good on paper; the problem is that neither the EMA nor the FDA approved them for that, and in Spain they are not authorised for use in men.
Online medical assessment, prescription when appropriate and 1:1 follow-up with this team.